Loading...
MIRA Pharmaceuticals, Inc.
MIRA•NASDAQ
Healthcare
Drug Manufacturers - General
$1.47
$-0.03(-2.00%)

Financial performance has remained strong, with revenue growing from $0.00 in Q4 2023 to $0.00 in Q3 2024. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$4.16M in Q3 2024, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$2.08M. Net income dropped to -$2.04M, keeping EPS at -$0.14. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan